18 Jul Specific Biologics
Brent Stead, CEO
Oct. 6 | 4:45pm | FLW Ballroom G
Toronto, Ontario, Canada
(Private)
Specific Biologics is a venture-backed biotechnology company developing Dualase® to treat the untreatable with an industry-leading genome editing platform for precise, efficient, and programmable in vivo genome editing, with an initial therapeutic focus on the predictable collapse of pathogenic DNA repeat expansion disorders. The unique Dualase® two-site mechanism enables the seamless removal, repair, or insertion of both small and large DNA sequences, offering broad therapeutic potential, coupled with single AAV or all RNA delivery. Specific is advancing its first program to clinical proof-of-concept in C9ORF72 amyotrophic lateral sclerosis (ALS), the most frequent inherited genetic form of terminal ALS with no disease-modifying therapies available today.